Denali Therapeutics Inc., discovers, develops, and delivers barrier-crossing therapeutics for neurodegenerative, lysosomal, and other serious diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; DNL921 Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Denali Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Curaleaf Holdings (CURLF) and Denali Therapeutics (D...

Analysts Offer Insights on Healthcare Companies: Curaleaf Holdings (OtherCURLF) and Denali Therapeutics (DNLI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Denali Therapeutics (DNLI) and Intuitive Surgical (I...

Analysts Are Bullish on Top Healthcare Stocks: Denali Therapeutics (DNLI), Intuitive Surgical (ISRG)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Denali Therapeutics (DNLI) and Healthequity (HQY) wi...

Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Healthequity (HQY)

Jefferies analyst maintained a Buy rating on Denali Therapeutics today and set a price target of $40.00. The word on The Street in general, suggest...

Denali Therapeutics (DNLI) Receives a Buy from Jefferies

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Denali Therapeutics on May 8 and set a price target of $31.00. The compa...

Denali Therapeutics (DNLI) Gets a Buy from Bank of America Securities

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Silence Therapeutics (SLN), Aclaris Therapeutics (AC...

Current Quarter	$-0.72	Next Quarter	$-0.68
Current Year	$-2.74	Next Year	$-2.54
QoQ Growth	+5.6%	YoY Growth	+7.3%
3Y EPS CAGR	-4.5%	Target Price	$34.57
Consensus	Buy	Upside	+78.4%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DNLI	$19.38	+3.97%	2.30M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DNLI	$19.38	+4.0%	2.30M
3
4
5
6

DNLI

DNLI

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Denali Therapeutics Inc. Data in Excel

Get Denali Therapeutics Inc. Data in Excel